Influencing factors of radioiodine therapy in hyperthyroidism in adults

RADIOCHEMISTRY, RADIOPHARMACEUTICALS AND NUCLEAR MEDICINE

Influencing factors of radioiodine therapy in hyperthyroidism in adults

XU Jiehua，

ZHANG Zikang，

CHENG Muhua，

WANG Ping，

WU Chunxing，

SHAN Hong

Nuclear Science and Techniques

Vol.18, No.5

pp.294-297

Published in print 20 Oct 2007

DOI：10.1016/S1001-8042(07)60064-5

CLC：R817.5,R581.1

46900

The study was to evaluate factors affecting outcome of ¹³¹I therapy in hyperthyroidism for optimizing the method. Data from 213 patients who received ¹³¹I treatment from July 2003 to July 2005 in our department were retrospectively analyzed. Factors possibly contributing to the outcome of the ¹³¹I therapy were analyzed, including gender, age, history of antithyroid drug, thyroid volume, duration of disease and radioactive iodine uptake rate. Multivariate analysis was done. The rates of euthyroidism and hypothyroidism were 69% and 8.5%, respectively, after one time ¹³¹I therapy. Multivariate analysis of the patients showed no statistically significant factors affecting the outcome of ¹³¹I therapy. The study showed that ¹³¹I dose can be directly calculated, and this simplifies the dose-determined method and individualizes the therapy.

Iodine-131HyperthyroidismFactorsAdult

References

[1]

Franklyn J A, Daykin J, Holder R, et al. QJM, 1995, 88(3): 175-180.

[2]

Safe A F, Maxwell R T. Br J Clin Pract. 1990, 44(10): 393-395.

[3]

Ratcliffe G E, Fogelman I, Maisey M N. Br J Radiol, 1986, 59(707): 1105-1107.

[4]

Watson A B, Brownlie B E W, Frampton C M, et al. Clin Endocrinol (Oxf), 1988, 28(5): 487-496.

[5]

Nordyke R A, Gilbert F I. J Nucl Med, 1991, 32(3): 411-416.

[6]

De Bruin T W A, Croon C D L, De Klerk J M H, et al. J Intern Med, 1994, 236(5): 507-513.

[7]

Torring O, Tallstedt L, Wallin G, et al. J Clin Endocrinol Metab, 1996, 81(8): 2986-2993.

[8]

Rosenthall L. J Can Assoc Radiol, 1972, 23(3): 171-175.

[9]

Sridama V, McCormick M, Kaplan E L, et al. N Engl J Med, 1984, 311(7): 426-432.

[10]

Willemsen U F, Knesewitsch P, Kreisig T, et al. Eur J Nucl Med, 1993, 20(11): 1051-1055.

[11]

Kung A W C, Choi P, Lam K S L, et al. Clin Radiol, 1990, 42(1): 52-54.

[12]

Peters H, Fischer C, Bogner U, et al. Thyroid, 1997, 7(2): 247-251.

[13]

Sabri O, Zimny M, Schulz G, et al. J Clin Endocrinol Metab, 1999, 84(4): 1229-1233.

[14]

Braga M, Walpert N, Burch H B, et al. Thyroid, 2002, 12(2): 135-139.

[15]

Sabri O, Zimny M, Schreckenberger M, et al. Nuklearmedizin, 2001, 40(1): 1-6.

[16]

Ruchala M, Sowinski J, Dolata M, et al. Nucl Med Rev Cent East Eur, 2005, 8(1): 28-32.

[17]

Listewnik M H. Ann Acad Med Stetin, 2000, 46: 109-121.

[18]

Veliz J, Pineda G, Arancibia P, et al. Rev Med Chil, 2000, 128(6): 609-612.